Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Organogenesis Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Organogenesis Holdings' CEO'su Gary Gillheeney, Jan2014 tarihinde atandı, in görev süresi 10.75 yıldır. in toplam yıllık tazminatı $ 6.24M olup, şirket hissesi ve opsiyonları dahil olmak üzere 14.6% maaş ve 85.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.63% ine doğrudan sahiptir ve bu hisseler € 2.14M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 7.1 yıl ve 3.9 yıldır.

Anahtar bilgiler

Gary Gillheeney

İcra Kurulu Başkanı

US$6.2m

Toplam tazminat

CEO maaş yüzdesi	14.6%
CEO görev süresi	10.8yrs
CEO sahipliği	0.6%
Yönetim ortalama görev süresi	7.1yrs
Yönetim Kurulu ortalama görev süresi	3.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Gary Gillheeney'un ücretlendirmesi Organogenesis Holdings'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$17m
Mar 31 2024	n/a	n/a	US$6m
Dec 31 2023	US$6m	US$909k	US$5m
Sep 30 2023	n/a	n/a	US$13m
Jun 30 2023	n/a	n/a	US$10m
Mar 31 2023	n/a	n/a	US$13m
Dec 31 2022	US$6m	US$883k	US$16m
Sep 30 2022	n/a	n/a	US$59m
Jun 30 2022	n/a	n/a	US$71m
Mar 31 2022	n/a	n/a	US$83m
Dec 31 2021	US$4m	US$835k	US$94m
Sep 30 2021	n/a	n/a	US$62m
Jun 30 2021	n/a	n/a	US$69m
Mar 31 2021	n/a	n/a	US$43m
Dec 31 2020	US$3m	US$823k	US$17m
Sep 30 2020	n/a	n/a	-US$5m
Jun 30 2020	n/a	n/a	-US$37m
Mar 31 2020	n/a	n/a	-US$42m
Dec 31 2019	US$1m	US$819k	-US$39m
Sep 30 2019	n/a	n/a	-US$46m
Jun 30 2019	n/a	n/a	-US$48m
Mar 31 2019	n/a	n/a	-US$58m
Dec 31 2018	US$3m	US$798k	-US$65m
Sep 30 2018	n/a	n/a	-US$60m
Jun 30 2018	n/a	n/a	-US$52m
Mar 31 2018	n/a	n/a	-US$32m
Dec 31 2017	US$1m	US$780k	-US$9m

Tazminat ve Piyasa: Gary 'nin toplam tazminatı ($USD 6.24M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.29M ).

Tazminat ve Kazançlar: Gary şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Gary Gillheeney (69 yo)

10.8yrs

Görev süresi

US$6,244,671

Tazminat

Mr. Gary S. Gillheeney, Sr. has been the Chief Executive Officer and President of Organogenesis Holdings Inc. since 2014 and has been its Director since December 10, 2018 & serves as its Chair of the Board...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gary Gillheeney	President	10.8yrs	US$6.24m	0.63% € 2.4m
David Francisco	Chief Financial Officer	3.7yrs	US$1.63m	0.048% € 185.7k
Patrick Bilbo	Chief Operating Officer	7.1yrs	US$2.16m	0.26% € 1.0m
Lori Freedman	Chief Administrative & Legal Officer	7.8yrs	US$1.99m	0.063% € 244.1k
Brian Grow	Chief Commercial Officer	7.1yrs	US$1.92m	0.078% € 302.0k
William Kolb	Secretary	no data	Veri yok	Veri yok
Robert Cavorsi	Vice President of Strategy	3.8yrs	Veri yok	0.11% € 406.5k

7.1yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: 2PQ 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gary Gillheeney	President	5.8yrs	US$6.24m	0.63% € 2.4m
Glenn Nussdorf	Director	21.8yrs	Veri yok	11.29% € 43.5m
Alan Ades	Director	21.8yrs	Veri yok	11.5% € 44.3m
Arthur Leibowitz	Lead Independent Director	5.8yrs	US$291.46k	0.10% € 397.3k
Robert Ades	Director	3.9yrs	Veri yok	Veri yok
Jon Giacomin	Independent Director	3.4yrs	US$265.00k	0.068% € 261.3k
Michele Korfin	Independent Director	2.4yrs	US$226.98k	0.068% € 260.8k
Prathyusha Duraibabu	Independent Director	2.9yrs	US$240.00k	0.071% € 273.0k
David Erani	Director	3.9yrs	Veri yok	Veri yok
Michael Driscoll	Independent Director	2.7yrs	US$230.52k	Veri yok
Gilberto Quintero	Independent Director	2.4yrs	US$226.98k	0.068% € 260.8k

3.9yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 2PQ 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.9 yıldır).

Organogenesis Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Organogenesis Holdings Inc., Annual General Meeting, Jun 20, 2024

Insider recently sold €70k worth of stock

High number of new directors

Insider recently sold €94k worth of stock

High number of new directors

Insider recently sold €860k worth of stock

Recent updates

Organogenesis Holdings Inc. to Report Q3, 2024 Results on Nov 12, 2024

Second quarter 2024 earnings released: US$0.13 loss per share (vs US$0.04 profit in 2Q 2023)

Organogenesis Holdings Inc. Shares Renu Program Update

Investor sentiment deteriorates as stock falls 18%

Organogenesis Holdings Inc. to Report Q2, 2024 Results on Aug 08, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 28%

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

First quarter 2024 earnings released: US$0.016 loss per share (vs US$0.023 loss in 1Q 2023)

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Organogenesis Holdings Inc., Annual General Meeting, Jun 20, 2024

Organogenesis Holdings Inc. to Report Q1, 2024 Results on May 09, 2024

Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

Investor sentiment deteriorates as stock falls 18%

New minor risk - Earnings quality

Organogenesis Holdings Inc. Provides Earnings Guidance for the First Quarter and for the Year Ending December 31, 2024

Full year 2023 earnings released: EPS: US$0.038 (vs US$0.12 in FY 2022)

Organogenesis Holdings Inc. to Report Q4, 2023 Results on Feb 29, 2024

Insider recently sold €70k worth of stock

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 17%

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2023

Third quarter 2023 earnings released: EPS: US$0.024 (vs US$0.002 in 3Q 2022)

High number of new directors

Organogenesis Holdings Inc. to Report Q3, 2023 Results on Nov 09, 2023

Organogenesis Holdings Inc. Withdraws Earnings Guidance for the the 2023

Second quarter 2023 earnings released: EPS: US$0.04 (vs US$0.067 in 2Q 2022)

Investor sentiment deteriorates as stock falls 19%

Investor sentiment improves as stock rises 23%

Organogenesis Holdings Inc. to Report Q2, 2023 Results on Aug 09, 2023

Organogenesis Holdings Inc. to Report Q2, 2023 Results on Aug 09, 2023

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 15%

Investor sentiment improves as stock rises 47%

Organogenesis Holdings Inc. Provides Earnings Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: US$0.023 loss per share (vs US$0.001 profit in 1Q 2022)

Insider recently sold €94k worth of stock

Investor sentiment deteriorates as stock falls 21%

Full year 2022 earnings released: EPS: US$0.12 (vs US$0.73 in FY 2021)

Investor sentiment deteriorates as stock falls 18%

Organogenesis Holdings Inc. to Report Q4, 2022 Results on Mar 01, 2023

High number of new directors

Third quarter 2022 earnings released: EPS: US$0.002 (vs US$0.098 in 3Q 2021)

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

Organogenesis Holdings Inc. to Report Q3, 2022 Results on Nov 09, 2022

Investor sentiment deteriorated over the past week

Organogenesis Receives FDA Clearance for Next Generation PuraPly Surgical Solution

Second quarter 2022 earnings released: EPS: US$0.067 (vs US$0.16 in 2Q 2021)

Organogenesis Holdings Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

Organogenesis Holdings Inc. to Report Q2, 2022 Results on Aug 09, 2022

Insider recently sold €860k worth of stock

Insider recently bought €58k worth of stock

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

First quarter 2022 earnings released: EPS: US$0.001 (vs US$0.078 in 1Q 2021)

Organogenesis Holdings Inc. Announces Board Changes

High number of new directors

Organogenesis Holdings Inc., Annual General Meeting, Jun 23, 2022

Organogenesis Holdings Inc. to Report Q1, 2022 Results on May 10, 2022

High number of new directors

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

Now 21% undervalued after recent price drop

Organogenesis Appoints Michael J. Driscoll to Board of Directors

Organogenesis Holdings Inc. to Report Q4, 2021 Results on Mar 01, 2022

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Organogenesis Holdings Inc. Investors

Pomerantz LLP Files Class Action Lawsuit Against Organogenesis Holdings Inc

Director recently bought €219k worth of stock